Literature DB >> 3827600

Passive immunization of mice with monoclonal antibodies raised against tick-borne encephalitis virus. Brief report.

R J Phillpotts, J R Stephenson, J S Porterfield.   

Abstract

Adult Balb/c mice were passively immunized with monoclonal antibodies (100 micrograms/mouse) raised against tick-borne encephalitis (TBE) virus then challenged 24 hours later s.c. with 10 LD50 of TBE virus (Nëudorfl isolate). None of the mice showed evidence of premature death although all except one of the monoclonal antibodies tested are capable of enhancing the infectivity of TBE virus in the Fc receptor-bearing mouse macrophage-like cell line P 388 D 1. The ability of monoclonal antibodies to neutralize TBE virus in vitro, and to fix complement was examined, and of these properties only a single monoclonal antibody, which was able to neutralize virus, was also able to protect mice against virus challenge.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3827600     DOI: 10.1007/bf01310983

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  17 in total

Review 1.  Flaviviridae.

Authors:  E G Westaway; M A Brinton; M C Horzinek; A Igarashi; L Kääriäinen; D K Lvov; J S Porterfield; P K Russell; D W Trent
Journal:  Intervirology       Date:  1985       Impact factor: 1.763

2.  Antigenic variation among members of the tick-borne encephalitis complex.

Authors:  J R Stephenson; J M Lee; P D Wilton-Smith
Journal:  J Gen Virol       Date:  1984-01       Impact factor: 3.891

3.  A topological and functional model of epitopes on the structural glycoprotein of tick-borne encephalitis virus defined by monoclonal antibodies.

Authors:  F X Heinz; R Berger; W Tuma; C Kunz
Journal:  Virology       Date:  1983-04-30       Impact factor: 3.616

4.  Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution.

Authors:  C M Rice; E M Lenches; S R Eddy; S J Shin; R L Sheets; J H Strauss
Journal:  Science       Date:  1985-08-23       Impact factor: 47.728

5.  Passive hemolysis-in-gel with Togaviridae arboviruses.

Authors:  S Y Gaidamovich; E E Melnikova
Journal:  Intervirology       Date:  1980       Impact factor: 1.763

6.  Biological activities of the structural proteins of Japanese encephalitis virus.

Authors:  T Takegami; H Miyamoto; H Nakamura; K Yasui
Journal:  Acta Virol       Date:  1982-09       Impact factor: 1.162

7.  Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses.

Authors:  M W Brandriss; J J Schlesinger; E E Walsh; M Briselli
Journal:  J Gen Virol       Date:  1986-02       Impact factor: 3.891

8.  Production of monoclonal antibodies with haemagglutination-inhibition activity to the Skalica strain from the tick-borne encephalitis complex.

Authors:  M Novák; M Gresíková; M Sekeyová; G Russ; J Zikán; M Pospísil; F Ciampor
Journal:  Acta Virol       Date:  1983-01       Impact factor: 1.162

9.  Pathogenesis and immune response of vaccinated and unvaccinated rhesus monkeys to tick-borne encephalitis virus.

Authors:  P Hambleton; J R Stephenson; A Baskerville; C N Wiblin
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

10.  Antigenic relationships among viruses of the tick-borne encephalitis complex as studied by monoclonal antibodies.

Authors:  M Gresíková; M Sekeyová
Journal:  Acta Virol       Date:  1984-01       Impact factor: 1.162

View more
  12 in total

1.  Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Authors:  Erin Mehlhop; Camilo Ansarah-Sobrinho; Syd Johnson; Michael Engle; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

Review 2.  Closing the door on flaviviruses: entry as a target for antiviral drug design.

Authors:  Rushika Perera; Mansoora Khaliq; Richard J Kuhn
Journal:  Antiviral Res       Date:  2008-06-11       Impact factor: 5.970

3.  Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein.

Authors:  T R Kreil; E Maier; S Fraiss; M M Eibl
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

4.  Antigenic analysis of West Nile virus strains using monoclonal antibodies.

Authors:  T G Besselaar; N K Blackburn
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

5.  Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein.

Authors:  Theodore Oliphant; Grant E Nybakken; Michael Engle; Qing Xu; Christopher A Nelson; Soila Sukupolvi-Petty; Anantha Marri; Bat-El Lachmi; Udy Olshevsky; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

6.  Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model.

Authors:  T R Kreil; M M Eibl
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

7.  Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.

Authors:  F Guirakhoo; K Pugachev; Z Zhang; G Myers; I Levenbook; K Draper; J Lang; S Ocran; F Mitchell; M Parsons; N Brown; S Brandler; C Fournier; B Barrere; F Rizvi; A Travassos; R Nichols; D Trent; T Monath
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection.

Authors:  Theodore C Pierson; Qing Xu; Steevenson Nelson; Theodore Oliphant; Grant E Nybakken; Daved H Fremont; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-04-19       Impact factor: 21.023

Review 9.  Progress on the development of therapeutics against West Nile virus.

Authors:  Michael S Diamond
Journal:  Antiviral Res       Date:  2009-06-06       Impact factor: 5.970

10.  Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice.

Authors:  Michael J Engle; Michael S Diamond
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.